Genitourinary Cancer Research

Genitourinary Cancer Research

Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.

Clinical Trials

A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Locally Advanced Urothelial Cancer with Selected FGFR Gene Alterations
Patient perceptions regarding routine oncologic follow-up for urologic malignancies.
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase 2b, Single- Arm, Multicenter Trial to Evaluate the Effficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrance
Use of a Multiplexed Molecular Biomarker Test Cxbladder, in Real World Decision Making to Provide Clinical Utility Using a Randomized Design
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
Phase 2 Study of Bladder-SparIng ChemoradiatioN with CIPosItive bladdeR cancEr (INSPIRE)EA8185
NRG-GU005 Phase III IGRT and SBRT VS IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer
Computer-Aided Diagnosis of Cancer in Urinary Tract on Multi-Detector Row CT Urography
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Follow up for patients on Phase lb Clinical Trial of Eribulin Mesylate and the PD-Ll Monoclonal Antibody, Avelumab, in Cisplatin Ineligible or Platinum Resistant Metastatic Urothelial Cell Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
Enhancing Patient Resilience During Multimodal Therapy for Bladder Cancer
Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens
Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome
Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.
A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Locally Advanced Urothelial Cancer with Selected FGFR Gene Alterations
Patient perceptions regarding routine oncologic follow-up for urologic malignancies.
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase 2b, Single- Arm, Multicenter Trial to Evaluate the Effficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle- Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrance
Use of a Multiplexed Molecular Biomarker Test Cxbladder, in Real World Decision Making to Provide Clinical Utility Using a Randomized Design
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
Phase 2 Study of Bladder-SparIng ChemoradiatioN with CIPosItive bladdeR cancEr (INSPIRE)EA8185
NRG-GU005 Phase III IGRT and SBRT VS IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer
Computer-Aided Diagnosis of Cancer in Urinary Tract on Multi-Detector Row CT Urography
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Follow up for patients on Phase lb Clinical Trial of Eribulin Mesylate and the PD-Ll Monoclonal Antibody, Avelumab, in Cisplatin Ineligible or Platinum Resistant Metastatic Urothelial Cell Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
Enhancing Patient Resilience During Multimodal Therapy for Bladder Cancer
Creation of a Clinical and Pathologic Tissue Microarray Registry for Radical Cystectomy Specimens
Complications in Patients Undergoing Radical Cystectomy for Bladder Cancer
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)